{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:47:00Z","timestamp":1786866420252,"version":"build-2736575974"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00425","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T04:32:16Z","timestamp":1597811536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Metformin in Pulmonary Hypertension in Left Heart Disease"],"prefix":"10.3389","volume":"7","author":[{"given":"Vinaya","family":"Mulkareddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/dmrr.480","article-title":"The incidence of congestive heart failure associated with antidiabetic therapies","volume":"21","author":"Nichols","year":"2005","journal-title":"Diabetes Metab Res Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/dom.13938","article-title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?","volume":"22","author":"Inzucchi","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American college of cardiology task force on expert consensus decision pathways","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/1573403X09666131117164122","article-title":"Pulmonary hypertension: types and treatments","volume":"11","author":"Rose-Jones","year":"2015","journal-title":"Curr Cardiol Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachiery","year":"2019","journal-title":"Eur Respir J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/CIRCRESAHA.118.313650","article-title":"Medical therapy for heart failure associated with pulmonary hypertension","volume":"124","author":"Zelt","year":"2019","journal-title":"Circ Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10741-019-09810-4","article-title":"Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF","volume":"25","author":"Ghio","year":"2020","journal-title":"Heart Fail Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1161\/CIRCHEARTFAILURE.110.960864","article-title":"Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure","volume":"4","author":"Aronson","year":"2011","journal-title":"Circ Heart Fail."},{"key":"B13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12265-017-9756-y","article-title":"Precision medicine for heart failure with preserved ejection fraction: an overview","volume":"10","author":"Shah","year":"2017","journal-title":"J Cardiovasc Transl Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.167586","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the Adult: a report of the American college of cardiology\/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the International society for heart and lung transplantation: endorsed by the heart rhythm society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cardfail.2008.04.001","article-title":"Heart failure and diabetes mellitus: epidemiology and management of an alarming association","volume":"14","author":"Cohen-Solal","year":"2008","journal-title":"J Card Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0002-9149(97)00505-5","article-title":"Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss","volume":"80","author":"Alpert","year":"1997","journal-title":"Am J Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10741-013-9387-6","article-title":"Animal models of insulin resistance and heart failure","volume":"19","author":"Velez","year":"2014","journal-title":"Heart Fail Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/eurjhf\/hfq168","article-title":"Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients","volume":"13","author":"Willemsen","year":"2011","journal-title":"Eur J Heart Fail."},{"key":"B28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/HCO.0b013e3283031ab3","article-title":"Impact of diabetes and hypertension on the heart","volume":"23","author":"Pieske","year":"2008","journal-title":"Curr Opin Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11892-009-0014-9","article-title":"The failing diabetic heart: focus on diastolic left ventricular dysfunction","volume":"9","author":"van Heerebeek","year":"2009","journal-title":"Curr Diab Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1734-1140(09)70016-7","article-title":"Molecular determinants of heart failure with normal left ventricular ejection fraction","volume":"61","author":"Borbely","year":"2009","journal-title":"Pharmacol Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00125-002-0956-9","article-title":"Abnormal metabolic fate of nitric oxide in Type I diabetes mellitus","volume":"45","author":"Milsom","year":"2002","journal-title":"Diabetologia."},{"key":"B32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature."},{"key":"B33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e004796","DOI":"10.1161\/JAHA.113.004796","article-title":"Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart","volume":"2","author":"Sen","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000746","article-title":"Heart disease and stroke statistics-2020 update: a report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"Vanderpool","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jacc.2011.06.076","article-title":"Pulmonary pressures and death in heart failure: a community study","volume":"59","author":"Bursi","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J Card Fail."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjcard.2006.11.052","article-title":"Prognostic importance of pulmonary hypertension in patients with heart failure","volume":"99","author":"Kjaergaard","year":"2007","journal-title":"Am J Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation."},{"key":"B42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International randomized survival trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J."},{"key":"B44","unstructured":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial126877\n            RedfieldMM\n            ChenHH\n            BorlaugBA\n            SemigranMJ\n            LeeKL\n            LewisG\n          10.1001\/jama.2013.202423478662JAMA.3092013"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia."},{"key":"B46","first-page":"212","article-title":"Effect of metformin on glucose metabolism in mouse soleus muscle","volume":"12","author":"Bailey","year":"1986","journal-title":"Diabete Metab."},{"key":"B47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201801-0022LE","article-title":"Metformin therapy for pulmonary hypertension associated with heart failure with preserved ejection fraction versus pulmonary arterial hypertension","volume":"198","author":"Goncharov","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.115.018935","article-title":"SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"133","author":"Lai","year":"2016","journal-title":"Circulation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fcvm.2019.00110","article-title":"Heart failure with preserved ejection fraction and adipose tissue: a story of two tales","volume":"6","author":"Oh","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e015154","DOI":"10.1161\/JAHA.119.015154","article-title":"Metformin improves cardiac metabolism and function, and prevents left ventricular hypertrophy in spontaneously hypertensive rats","volume":"9","author":"Li","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2337\/db11-1132","article-title":"Metformin prevents the development of chronic heart failure in the SHHF rat model","volume":"61","author":"Cittadini","year":"2012","journal-title":"Diabetes."},{"key":"B52","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.117.031735","article-title":"Repurposing metformin for cardiovascular disease","volume":"137","author":"Rena","year":"2018","journal-title":"Circulation."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1093\/eurheartj\/ehz203","article-title":"A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial","volume":"40","author":"Mohan","year":"2019","journal-title":"Eur Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/eurheartj\/ehq289","article-title":"Metformin in insulin resistant LV dysfunction, a double-blind, placebo controlled trial (TAYSIDE trial)","volume":"31","author":"Wong","year":"2010","journal-title":"Eur Heart J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11906-014-0524-y","article-title":"Metabolic dysfunction in pulmonary arterial hypertension","volume":"17","author":"Assad","year":"2015","journal-title":"Curr Hypertens Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0735-1097(20)31579-5","article-title":"Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta regression analysis","volume":"75","author":"Halabi","year":"2020","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T04:32:21Z","timestamp":1597811541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":56,"alternative-id":["10.3389\/fmed.2020.00425"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00425","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"article-number":"425"}}